
Opinion|Videos|January 10, 2025
Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- With the recent NCCN update recommending pirtobrutinib as a second line or later option, and in light of the BRUIN CLL-321 data presented at the 2024 American Society of Hematology annual meeting, what factors should oncologists consider when incorporating newer agents like pirtobrutinib into the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)?
- What is the significance of novel Bruton tyrosine kinase (BTK) degraders such as NX-5948, and how might they fill therapeutic gaps in BTK-resistant or intolerant relapsed/refractory CLL populations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Low Trial Enrollment, Racial Disparities Limit Breast Cancer Treatment Innovation
4
Prospective Evidence Supports Tumor-First Multigene Testing in Ovarian Cancer
5
















































